Acts as a selective, reversible inhibitor of kallikrein, thereby inhibiting its action in initiating bradykinin production, part of the cascade of events in hereditary angioedema.
Therapeutic Effect(s):
Reduction in number of hereditary angioedema attacks.
Assess for signs (facial, laryngeal, or abdominal swelling, dyspnea, pain, nausea, vomiting, cramps, diarrhea) and frequency of hereditary angioedema attacks.
Monitor for signs and symptoms of severe hypersensitivity reactions (hives, urticaria, chest tightness, wheezing, hypotension, anaphylaxis) during or after injection.
SUBQ Remove vial or prefilled syringe from refrigerator 15 min before injecting to allow to warm to room temperature. Vials do not require reconstitution or dilution. Solution is clear to slightly opalescent, colorless to slightly yellow; do not administer solutions that are cloudy, discolored, or contain particulate matter. Do not shake vial or prefilled syringe. Withdraw dose from vial using an 18-gauge needle. Change to 27-gauge, ½-inch needle. Inject slowly into abdomen, thigh, or upper arm over 10–60 sec. Inject within 2 hr of preparing dosing syringe; may be refrigerated and used within 8 hr. Discard unused portion of vial or prefilled syringe.
May be administered by patient or caregiver in adults and children ≥12 yr; should be administered by health care professional or caregiver in children 2–<12 yr. Instruct patient or caregiver in correct technique for injection, storage, and place to discard syringes and needles.
Advise patient to notify health care professional immediately if signs and symptoms of hypersensitivity reaction occur.
Rep: Advise patient to notify health care professional if pregnancy is planned or suspected or if breastfeeding.